Add Saxenda (Liraglutide) for the Treatment of Obesity, US

Saxenda-%28Liraglutide%29-for-the-Treatment-of-Obesity%2C-US.md

@@ -0,0 +1,7 @@
+<br>Saxenda (liraglutide (rDNA origin)) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for the treatment of obesity and chronic weight management. Discovered and developed by Denmark-based pharmaceutical company Novo Nordisk, Saxenda is available as a solution in pre-filled, multi-dose pens that delivers doses of 0.6mg, 1.2mg, 1.8mg, 2.4mg or 3mg for subcutaneous injection. In December 2014,  [MedicGLP Official Support](https://rentry.co/47026-glp-weight-loss-a-revolutionary-approach-to-obesity-management) the FDA granted approval for Saxenda for the treatment of chronic weight management, combined with a reduced-calorie diet and physical activity. 27) and affected with an obesity-related condition such as type 2 diabetes, cardiovascular disease, hypertension or high cholesterol. The updated Saxenda injectable 3mg label was approved by the FDA in April 2017, based on findings from the SCALE™ Obesity and Pre-diabetes three-year trial, ensuring long-term safety and efficacy. The Scottish Medicines Consortium (SMC) assessed Saxenda and advised NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland in April 2022, resulting in its acceptance for restricted use.<br>
+
+<br>Obesity is a weight-related disorder that affects more than a third of adults in the US. The condition can be measured using BMI, the measurement of body fat based on the person’s height and weight. Obesity can lead to several health issues, including heart disease, type 2 diabetes, certain cancers and a reduced life expectancy. An [estimated](https://data.gov.uk/data/search?q=estimated) 80 million adults in the US suffer from obesity. Saxenda contains an active component called liraglutide, which is a glucagon-like peptide-1 ([Medic GLP Support](http://cgi.www5b.biglobe.ne.jp/~akanbe/yu-betsu/joyful/joyful.cgi?page=20)-1) analogue. The drug, which can be administered intravenously, reaches activated neurons in brain regions and regulates appetite and calorie intake. The FDA’s approval of Saxenda was based on results from three Phase III clinical trials SCALE (Satiety and Clinical Adiposity−Liraglutide Evidence in Nondiabetic and Diabetic people) studies, which were conducted for 56 weeks to evaluate the drug’s safety and efficacy. More than 5,000 participants were enrolled in the three SCALE clinical trials, each of whom was obese or overweight and with or without other weight-related conditions. The first SCALE clinical trial was a randomised, double-blind, placebo-controlled study. It enrolled 3,731 patients with obesity. The second study enrolled 635 patients with type 2 diabetes, who were either overweight or obese while the third study enrolled 422 patients with obesity. Patients were given 3mg of Saxenda daily or a placebo for 56 weeks and received counselling about lifestyle changes they needed to adopt related to a low-calorie diet and regular physical exercise. Results from the studies demonstrated that patients treated with Saxenda experienced a statistically significant weight reduction compared with placebo after 56 weeks. Patients treated with Saxenda achieved at least 5% and 10% weight loss compared to placebo.<br>
+
+<br>Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and  [Medic GLP Support](https://git.z1.mk/shermanhorrell/makayla2009/wiki/How-Protein-at-Breakfast-can-help-you-Lose-Weight) developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your [metabolism](https://twitter.com/search?q=metabolism) through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and  [MedicGLP](http://cgi.www5b.biglobe.ne.jp/~akanbe/yu-betsu/joyful/joyful.cgi?page=20) metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?<br>
+
+<br>1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. "Fiona’s update day 37!<br>